Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1399 studies found for:    HIV OR AIDS | Open Studies | NIH
Show Display Options
Download search resultsDownload the search results for:
HIV OR AIDS | Open Studies | NIH (1399 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans
Condition: HIV
Intervention:
2 Recruiting Brain Imaging for HIV-Associated Thinking and Mood Disorders
Conditions: Human Immunodeficiency Virus;   Neurocognitive Impairment
Intervention:
3 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
4 Recruiting Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Placebo
5 Not yet recruiting Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®-or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent subtype C gp120/MF59;   Biological: Bivalent subtype C gp120/AS01(B);   Biological: Placebo
6 Recruiting Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
Condition: HIV
Intervention: Biological: Entyvio (Vedolizumab)
7 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
8 Recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
9 Recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
10 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
11 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
12 Recruiting Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Efavirenz;   Drug: Raltegravir
13 Recruiting Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study
Condition: HIV Infection
Interventions: Drug: Aspirin 81 mg daily;   Drug: Atorvastatin 40 mg daily
14 Recruiting Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Condition: HIV Infections
Interventions: Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
15 Recruiting Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men
Condition: HIV Infections
Interventions: Drug: Cabotegravir tablets;   Drug: TDF/FTC tablets;   Drug: TDF/FTC placebo tablets;   Drug: CAB placebo tablets;   Drug: CAB LA;   Drug: Placebo for CAB LA
16 Recruiting Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: VRC01LS
17 Recruiting Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults
Condition: HIV-1
Intervention: Biological: VRC-HIVMAB080-00-AB (VRC01LS)
18 Recruiting Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Children Infected With HIV and TB
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: Raltegravir
19 Recruiting Evaluating the Safety and Pharmacokinetics of VRC01 and VRC01LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: VRC01LS
20 Recruiting Studies of Blood and Reproductive Fluids in HIV-Infected and Non-HIV-Infected Persons
Condition: HIV Infection
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.